137 related articles for article (PubMed ID: 18022268)
1. Preventing effects of a novel anti-parkinsonian agent zonisamide on dopamine quinone formation.
Asanuma M; Miyazaki I; Diaz-Corrales FJ; Miyoshi K; Ogawa N; Murata M
Neurosci Res; 2008 Jan; 60(1):106-13. PubMed ID: 18022268
[TBL] [Abstract][Full Text] [Related]
2. Dopamine- or L-DOPA-induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson's disease.
Asanuma M; Miyazaki I; Ogawa N
Neurotox Res; 2003; 5(3):165-76. PubMed ID: 12835121
[TBL] [Abstract][Full Text] [Related]
3. Methamphetamine-induced dopaminergic neurotoxicity is regulated by quinone-formation-related molecules.
Miyazaki I; Asanuma M; Diaz-Corrales FJ; Fukuda M; Kitaichi K; Miyoshi K; Ogawa N
FASEB J; 2006 Mar; 20(3):571-3. PubMed ID: 16403784
[TBL] [Abstract][Full Text] [Related]
4. [Pathogenesis of Parkinson's disease: a common pathway between alpha-synuclein and parkin and the mechanism of Lewy bodies formation].
Hattori N; Machida Y; Noda K
Rinsho Shinkeigaku; 2005 Nov; 45(11):905-7. PubMed ID: 16447759
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of vesicular monoamine transporter enhances vulnerability of dopaminergic cells: relevance to Parkinson's disease.
Choi HJ; Lee SY; Cho Y; Hwang O
Neurochem Int; 2005 Mar; 46(4):329-35. PubMed ID: 15707697
[TBL] [Abstract][Full Text] [Related]
6. Zonisamide attenuates α-synuclein neurotoxicity by an aggregation-independent mechanism in a rat model of familial Parkinson's disease.
Arawaka S; Fukushima S; Sato H; Sasaki A; Koga K; Koyama S; Kato T
PLoS One; 2014; 9(2):e89076. PubMed ID: 24586512
[TBL] [Abstract][Full Text] [Related]
7. Novel therapeutic effects of the anti-convulsant, zonisamide, on Parkinson's disease.
Murata M
Curr Pharm Des; 2004; 10(6):687-93. PubMed ID: 14965331
[TBL] [Abstract][Full Text] [Related]
8. Dopaminergic neuron-specific oxidative stress caused by dopamine itself.
Miyazaki I; Asanuma M
Acta Med Okayama; 2008 Jun; 62(3):141-50. PubMed ID: 18596830
[TBL] [Abstract][Full Text] [Related]
9. Cyclooxygenase-independent neuroprotective effects of aspirin against dopamine quinone-induced neurotoxicity.
Asanuma M; Miyazaki I; Kikkawa Y; Kimoto N; Takeshima M; Murakami S; Miyoshi K
Neurochem Res; 2012 Sep; 37(9):1944-51. PubMed ID: 22674083
[TBL] [Abstract][Full Text] [Related]
10. Protective effect of bromocriptine against BH4-induced Cath.a cell death involving up-regulation of antioxidant enzymes.
Lim JH; Kim SS; Boo DH; No H; Kang BY; Kim EM; Hwang O; Choi HJ
Neurosci Lett; 2009 Feb; 451(3):185-9. PubMed ID: 19146917
[TBL] [Abstract][Full Text] [Related]
11. Protective effects of baicalein against excess L-DOPA-induced dopamine quinone neurotoxicity.
Takeshima M; Murata M; Urasoe N; Murakami S; Miyazaki I; Asanuma M; Kita T
Neurol Res; 2011 Dec; 33(10):1050-6. PubMed ID: 22196758
[TBL] [Abstract][Full Text] [Related]
12. Protective and toxic roles of dopamine in Parkinson's disease.
Segura-Aguilar J; Paris I; Muñoz P; Ferrari E; Zecca L; Zucca FA
J Neurochem; 2014 Jun; 129(6):898-915. PubMed ID: 24548101
[TBL] [Abstract][Full Text] [Related]
13. Dopamine-dependent cytotoxicity of tetrahydrobiopterin: a possible mechanism for selective neurodegeneration in Parkinson's disease.
Choi HJ; Kim SW; Lee SY; Hwang O
J Neurochem; 2003 Jul; 86(1):143-52. PubMed ID: 12807434
[TBL] [Abstract][Full Text] [Related]
14. [Mechanism of specific dopaminergic neuronal death in Parkinson's disease].
Ogawa N; Asanuma M; Miyoshi K
Nihon Rinsho; 2004 Sep; 62(9):1629-34. PubMed ID: 15462376
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of rat brain mitochondrial electron transport chain activity by dopamine oxidation products during extended in vitro incubation: implications for Parkinson's disease.
Khan FH; Sen T; Maiti AK; Jana S; Chatterjee U; Chakrabarti S
Biochim Biophys Acta; 2005 Jun; 1741(1-2):65-74. PubMed ID: 15925494
[TBL] [Abstract][Full Text] [Related]
16. Formation of dopamine-mediated alpha-synuclein-soluble oligomers requires methionine oxidation.
Leong SL; Pham CL; Galatis D; Fodero-Tavoletti MT; Perez K; Hill AF; Masters CL; Ali FE; Barnham KJ; Cappai R
Free Radic Biol Med; 2009 May; 46(10):1328-37. PubMed ID: 19248830
[TBL] [Abstract][Full Text] [Related]
17. Drug treatment of Parkinson's disease. Time for phase II.
Drukarch B; van Muiswinkel FL
Biochem Pharmacol; 2000 May; 59(9):1023-31. PubMed ID: 10704931
[TBL] [Abstract][Full Text] [Related]
18. Neuroprotective effects of zonisamide target astrocyte.
Asanuma M; Miyazaki I; Diaz-Corrales FJ; Kimoto N; Kikkawa Y; Takeshima M; Miyoshi K; Murata M
Ann Neurol; 2010 Feb; 67(2):239-49. PubMed ID: 20225289
[TBL] [Abstract][Full Text] [Related]
19. Pramipexole has ameliorating effects on levodopa-induced abnormal dopamine turnover in parkinsonian striatum and quenching effects on dopamine-semiquinone generated in vitro.
Asanuma M; Miyazaki I; Diaz-Corrales FJ; Shimizu M; Tanaka K; Ogawa N
Neurol Res; 2005 Jul; 27(5):533-9. PubMed ID: 15978181
[TBL] [Abstract][Full Text] [Related]
20. Parkin protects human dopaminergic neuroblastoma cells against dopamine-induced apoptosis.
Jiang H; Ren Y; Zhao J; Feng J
Hum Mol Genet; 2004 Aug; 13(16):1745-54. PubMed ID: 15198987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
